Statistics from Altmetric.com
An estimated 1.7 billion people—23% of the world’s population—have been infected by Mycobacterium tuberculosis.1 It has been known for over five decades that, once someone has been infected with M. tuberculosis for more than 2–5 years, the risk of developing tuberculosis (TB) disease—barring a second infection or immunosuppressive condition—is small.2 Nevertheless, numerous publications and textbooks continue to cite a ‘rule of thumb’ that 5% of people with latent TB infection will develop reactivation TB disease after this initial high-risk period. Multiple recent analyses have reaffirmed that this 5% figure is a substantial overestimate.3 4
In this issue of Thorax, Trauer et al reanalyse data from 21 clinical trials of Bacille Calmette-Guérin (BCG) vaccination.5 Their comprehensive analysis provides yet another piece of evidence that the traditional conceptualisation of latent TB infection—as a static state in which people experience a constant, reasonably high risk of reactivation for many years, if not decades—should be abandoned.
Prior analyses have estimated that BCG-derived protection against TB disease may wane after about 10 years,6 though long-term follow-up data are scant. Trauer et al updated a prior meta-analysis of BCG vaccine trials7 to explore whether this waning of protection more likely reflects …
Contributors DD drafted the manuscript, revised the manuscript, and submitted the manuscript for publication.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.